Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Japan's Toyota Motor is expected to post its second consecutive quarterly profit drop when it reports third-quarter earnings ...

By Helen Reid and Isabelle Yr Carlsson COPENHAGEN (Reuters) -Danish jewellery maker Pandora said on Wednesday that its growth ...

By Juveria Tabassum and Waylon Cunningham (Reuters) -Chipotle Mexican Grill forecast tepid annual comparable sales growth on ...

International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the ...

The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition ...

The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

Veralto Corporation delivered all-time high annual sales of $5.2 billion in 2024, with 3.7% core sales growth and an adjusted earnings per share increase of 11% to $3.54. Free cash flow generation ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.